Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

9.250 -0.150 (-1.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 77,026
Open 9.420
Bid (Size) 9.000 (2)
Ask (Size) 9.500 (5)
Prev. Close 9.400
Today's Range 9.160 - 9.580
52wk Range 7.870 - 25.65
Shares Outstanding 14,828,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. – ANIK
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-42.9%
-42.9%
1 Month
+1.1%
+1.1%
3 Month
-17.8%
-17.8%
6 Month
-38.5%
-38.5%
1 Year
-61.9%
-61.9%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For July 30, 2025
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Nutex, Anika, Fluor, and Inspire Medical and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors
From Kirby McInerney LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Anika (ANIK) Q2 Revenue Beats by 4%
Via The Motley Fool
Topics Economy
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Reports Mixed Q2 2025 Results with Revenue Beat but EPS Miss, Shares Drop 9% in Pre-Market
Via Chartmill
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
From Anika Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Anika Therapeutics Inc. - Common Stock publicly traded?
Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Anika Therapeutics Inc. - Common Stock trade on?
Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?
The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market
What is the current price of Anika Therapeutics Inc. - Common Stock?
The current price of Anika Therapeutics Inc. - Common Stock is 9.250
When was Anika Therapeutics Inc. - Common Stock last traded?
The last trade of Anika Therapeutics Inc. - Common Stock was at 10/01/25 04:00 PM ET
What is the market capitalization of Anika Therapeutics Inc. - Common Stock?
The market capitalization of Anika Therapeutics Inc. - Common Stock is 137.16M
How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?
Anika Therapeutics Inc. - Common Stock has 137M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.